The purpose of breast cancer screening is to find cancers early to reduce mortality and to allow successful treatment with less aggressive therapy. Mammography is the gold standard for breast cancer screening. Its efficacy in reducing mortality from breast cancer was proven in randomized controlled trials (RCTs) conducted from the early 1960s to the mid 1990s. Panels that recommend breast cancer screening guidelines have traditionally relied on the old RCTs, which did not include considerations of breast density, race/ethnicity, current hormone therapy, and other risk factors. Women do not all benefit equally from mammography. Mortality reduction is significantly lower in women with dense breasts because normal dense tissue can mask cancers on mammograms. Moreover, women with dense breasts are known to be at increased risk. To provide equity, breast cancer screening guidelines should be created with the goal of maximizing mortality reduction and allowing less aggressive therapy, which may include decreasing the interval between screening mammograms and recommending consideration of supplemental screening for women with dense breasts. This review will address the issue of dense breasts and the impact on the stage of breast cancer at the time of diagnosis, and discuss options for supplemental screening.
Homepage - ESGO - European Society of Gynaecological Oncology
Current Oncology, Free Full-Text
Radiation Oncology Question Review, Second Edition – Radiation Oncology Board Review Guide by Expert Radiation Oncologists from Cleveland Clinic Taussig Cancer Institute, Book and Free eBook: 9780826135667: Medicine & Health Science Books @
Handpicked for you: sessions for pharmacists at Oncology Professional Care 2023 - BOPA
National Comprehensive Cancer Network - Home
Home Annals of Surgical Oncology
Current Oncology, Free Full-Text
Frontiers Association of Lipoprotein(a)-Associated Mortality and
Big data in basic and translational cancer research
Current Oncology 2021 - Browse Issues
First-line Atezolizumab Monotherapy Versus Single-agent, 43% OFF
Home Current Treatment Options in Oncology
Current Oncology An Open Access Journal from MDPI